Literature DB >> 29748307

Infant nasal nitric oxide over time: natural evolution and impact of respiratory tract infection.

June K Marthin1, Maria C Philipsen1, Susanne Rosthoj2, Kim G Nielsen1.   

Abstract

Nasal nitric oxide (NO) discriminates between patients with primary ciliary dyskinesia (PCD) and healthy individuals. We report feasibility of measurement and natural evolution of nasal NO and upon the impact of respiratory tract infection (RTI) on nasal NO in healthy infants (HI), followed from birth until age 2 years, with comparison to nasal NO in infant PCD.Tidal-breathing nasal NO measurements were performed at scheduled visits at 2 weeks old and at 4, 8, 12, 18 and 24 months old, with extra visits during RTIs. Historical nasal NO measurements for infant PCD were included for comparison.Altogether, 224 nasal NO measurements were performed in 44 enrolled infants. Median newborn nasal NO was 46 ppb (interquartile range (IQR) 29-69 ppb), increasing at a rate of 5.4% per month up to 283 ppb (IQR 203-389 ppb) at the age of 2 years. RTIs in 27 out of 44 infants temporarily suppressed nasal NO by 79%. Values for nasal NO in seven infants with PCD ranged from 6-80 ppb. The success rate to accept nasal NO sampling was 223 out of 224 measurements (99.6%).Tidal-breathing nasal NO measurement was indeed feasible in infancy and nasal NO in HI increased significantly up to 2 years of age, in opposition to nasal NO in PCD cases, which stayed low past 2 years of age. RTI episodes caused marked, temporary reductions in nasal NO in HI indistinguishable from that in infant PCD, suggesting that nasal NO should be measured in RTI-free intervals.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29748307     DOI: 10.1183/13993003.02503-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Proof of Concept: Very Rapid Tidal Breathing Nasal Nitric Oxide Sampling Discriminates Primary Ciliary Dyskinesia from Healthy Subjects.

Authors:  Mathias G Holgersen; June K Marthin; Kim G Nielsen
Journal:  Lung       Date:  2019-02-14       Impact factor: 2.584

2.  Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols.

Authors:  Adam J Shapiro; Sharon D Dell; Benjamin Gaston; Michael O'Connor; Nadzeya Marozkina; Michele Manion; Milan J Hazucha; Margaret W Leigh
Journal:  Ann Am Thorac Soc       Date:  2020-02

3.  Nasal Nitric Oxide in Primary Immunodeficiency and Primary Ciliary Dyskinesia: Helping to Distinguish Between Clinically Similar Diseases.

Authors:  Zofia N Zysman-Colman; Kimberley R Kaspy; Reza Alizadehfar; Keith R NyKamp; Maimoona A Zariwala; Michael R Knowles; Donald C Vinh; Adam J Shapiro
Journal:  J Clin Immunol       Date:  2019-03-26       Impact factor: 8.317

4.  Feasibility of nasal NO screening in healthy newborns.

Authors:  Flurina Buechel; Jakob Usemann; A Aline; Peter Salfeld; Alexander Moeller; Andreas Jung
Journal:  Pediatr Pulmonol       Date:  2021-10-01

5.  Proceedings of the 4th BEAT-PCD Conference and 5th PCD Training School.

Authors:  Laura E Gardner; Katie L Horton; Amelia Shoemark; Jane S Lucas; Kim G Nielsen; Helene Kobbernagel; Bruna Rubbo; Robert A Hirst; Panayiotis Kouis; Nicola Ullmann; Ana Reula; Nisreen Rumman; Hannah M Mitchison; Andreia Pinto; Charlotte Richardson; Anne Schmidt; James Thompson; René Gaupmann; Maciej Dabrowski; Pleasantine Mill; Siobhan B Carr; Dominic P Norris; Claudia E Kuehni; Myrofora Goutaki; Claire Hogg
Journal:  BMC Proc       Date:  2020-06-19

6.  An international survey on nasal nitric oxide measurement practices for the diagnosis of primary ciliary dyskinesia.

Authors:  Nicole Beydon; Thomas Ferkol; Amanda Lea Harris; Murielle Colas; Stephanie D Davis; Eric Haarman; Claire Hogg; Emma Kilbride; Panayotis Kouis; Claudia E Kuehni; Philipp Latzin; Diana Marangu; June Marthin; Kim G Nielsen; Phil Robinson; Nisreen Rumman; Matthew Rutter; Woolf Walker; Jane S Lucas
Journal:  ERJ Open Res       Date:  2022-04-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.